Corinna Albers-Leischner
Dr. rer. nat.
Corinna Albers-Leischner
Sprachen
Deutsch (Muttersprache)
Englisch

Publikationen

Zurück
  • 2024
  • 2022
  • 2020
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
Vor

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
Gorantla S, Mueller T, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J
MOL ONCOL. 2024;18(2):415-430.

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
Illini O, Saalfeld F, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi S, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild S, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik J, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust D, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck T, Griesinger F, Jakopovic M, Hochmair M, Wermke M
INT J MOL SCI. 2024;25(7):.

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel H, Wiesweg M, Schildhaus H, Stratmann J, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld F, Wermke M, Merkelbach-Bruse S, Hillmer A, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S
ANN ONCOL. 2022;33(6):602-615.

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
Kreutmair S, Lippert L, Klingeberg C, Albers-Leischner C, Yacob S, Shlyakhto V, Mueller T, Mueller-Rudorf A, Yu C, Gorantla S, Miething C, Duyster J, Illert A
FRONT ONCOL. 2022;12:.

Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
Yu C, Gorantla S, Müller-Rudorf A, Müller T, Kreutmair S, Albers C, Jakob L, Lippert L, Yue Z, Engelhardt M, Follo M, Zeiser R, Huber T, Duyster J, Illert A
HAEMATOLOGICA. 2020;105(5):1285-1293.

Grb10 is involved in BCR-ABL-positive leukemia in mice
Illert A, Albers C, Kreutmair S, Leischner H, Peschel C, Miething C, Duyster J
LEUKEMIA. 2015;29(4):858-68.

GP130 activation induces myeloma and collaborates with MYC
Dechow T, Steidle S, Götze K, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U
J CLIN INVEST. 2014;124(12):5263-74.

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Albers C, Leischner H, Verbeek M, Yu C, Illert A, Peschel C, von Bubnoff N, Duyster J
LEUKEMIA. 2013;27(6):1416-8.

Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M
Illert A, Zech M, Moll C, Albers C, Kreutmair S, Peschel C, Bassermann F, Duyster J
J BIOL CHEM. 2012;287(45):37997-8005.

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML
Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J
BLOOD. 2012;119(17):4026-33.

An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis
Albers C, Illert A, Miething C, Leischner H, Thiede M, Peschel C, Duyster J
BLOOD. 2011;118(8):2200-10.

In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease
Hartmann N, Leithäuser F, Albers C, Duyster J, Möller P, Debatin K, Strauss G
LEUKEMIA. 2011;25(5):848-55.

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway
Markova B, Albers C, Breitenbuecher F, Melo J, Brümmendorf T, Heidel F, Lipka D, Duyster J, Huber C, Fischer T
ONCOGENE. 2010;29(5):739-51.

Letzte Aktualisierung aus dem FIS: 24.12.2024 - 23:34 Uhr